LACHMAN CONSULTANT SERVICES, INC.
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590
(516) 222-6222 • FAX (516) 683-1887

August 28, 2006

OVERNIGHT COURIER 8/28/06

Division of Dockets Management
Food and Drug Administration (HFA-305)
5630 Fishers Lane, Room 1061
Rockville, MD 20852

Withdrawal of Citizen Petition 2006P-0286

Dear Sir or Madam:

On July 14, 2006, the undersigned submitted the above-referenced petition on behalf of a client pursuant to 21 CFR 10.30 and in accordance with the regulations at 21 CFR 314.161, requesting the Commissioner of the Food and Drug Administration to provide a determination whether a listed drug, Phoslo (calcium acetate) Capsules eq 160 mg calcium, has been withdrawn for safety or effectiveness reasons, as outlined below.

We have been informed by the Food and Drug Administration that this product is still being marketed, and thus, we are requesting that the petition be withdrawn at this time.

Respectfully submitted,

Robert Pollock

Robert W. Pollock
Senior Vice President

RWP/pk

cc: Martin Shimer (Office of Generic Drugs)
Nicole Mueller (Office of Regulatory Policy, HFD-7)

R12P6240

2006P-0286 WDL 1